Table 6.
Patient characteristics and outcome of STZ CTx in PanNET
| Regimen, implementation (duration) | n | Radiologic response assessable, n (%) | Localisation | WHO tumour grading G1 (% of cohort) | Stage IV | STZ CTx 1st line | Time from initial diagnosis to therapy start (months) | Progressive disease at baseline | ORR | DCR | mPFS/TTP (months) | mOS (months) | Markers of response | Prognostic factors PFS/TTP | Prognostic factors OS | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Clewemar et al. [15] | STZ/5-FU 1981–2014 | 133 | 100 (75.2%) | 100% pancreas | 36% | 88% | 63.2% | n.ra | 32% | 28% | 92% | 23 | 51.9 | CgA decrease > 50% | Grading Stage IV | Grading Previous surgery |
| Dilz et al. [13] | STZ/5-FU 1998–2014 | 96 | 93 (96.8%) | 100% pancreas | 12% | 93.8% | 56.3% | 11.8 | 74% | 42.7% | 83.3% | 19.4 | 54.8 | CgA decrease >30% | Ki-67 > 15% | Ki-67 > 15% Metastatic sites ≥2 |
| Krug et al. [14] | STZ/Dox/5-FU 1995–2013 | 77 | 64 (83.1%) | 84.4% pancreas (+bronchial, duodenal, CUP-NEN) | 12% | 90.9% | 19.5% | 33 | n.ra | 34% | 72% | 16 | 28 | CgA decrease >30%, positive Octreo-Scan | Ki-67 > 10% | —b |
| Schrader et al. [16] | STZ/5-FU 2002–2018 | 30 | 28 (93.3%) | 100% pancreas | n.ra | 92.9% | 61% | n.ra | n.ra | 36% | 86% | 21 | 69 | —b | Previous surgery | —b |
| Lahner et al. | STZ/5-FU 2010–2018 | 50 | 50 (100%) | 100% pancreas | 6% | 96% | 54% | 6.5 | 100% | 38% | 76% | 12 | 38 | CgA decrease >30% | —b | Bone metastases Therapy line |
an.r. not reported
b— not found